# Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)

> **NCT06101277** · NA · RECRUITING · sponsor: **University of California, Davis** · enrollment: 300 (estimated)

## Conditions studied

- Esophageal Cancer
- Small Bowel Cancer
- Gastroesophageal-junction Cancer
- Gastric Cancer
- Colorectal Cancer
- Appendiceal Cancer
- Biliary Cancer
- Gall Bladder Cancer
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
- Oligoprogressive

## Interventions

- **DEVICE:** Ablative local therapy

## Key facts

- **NCT ID:** NCT06101277
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-10-05
- **Primary completion:** 2025-12-05
- **Final completion:** 2031-01-05
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2025-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06101277

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06101277, "Locally ablatIVe thErapy for oLigo-progressive gastrOintestiNal maliGnancies (LIVELONG)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06101277. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*